<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338362</url>
  </required_header>
  <id_info>
    <org_study_id>13-6069-A</org_study_id>
    <nct_id>NCT02338362</nct_id>
  </id_info>
  <brief_title>Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma</brief_title>
  <official_title>The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a commonly prescribed orally inhaled
      corticosteroid treatment will induce a clinically meaningful elevation in intraocular
      pressure, when administered to patients with ocular hypertension (OHT) or open-angle glaucoma
      (OAG). Based on the response to high-dose corticosteroids, this patient group is more likely
      than the normal population to demonstrate this adverse effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic and topical ophthalmic steroids have long been associated with ocular effects, such
      as glaucoma or cataracts.[Alfano JE; Bernstein HN et al. 1962; Bernstein HN et al. 1963;
      Becker B and Mills DW in Arch Ophthalm 1963; Becker B and Mills DW in JAMA 1963; Armaly MF
      1963 (1); Armaly MF 1963 (2); and Buckley RJ] Periocular steroid injections [Herschler J;
      Kalina RE] and steroids applied to periocular skin [Aggarwal RK et al.] have also been
      reported to increase intraocular pressure (IOP) and raised IOP is the major risk factor for
      glaucoma.

      Ocular hypertension (OHT) is defined as an IOP above 21mmHg in one or both eyes without
      detectable glaucomatous damage. Primary open-angle glaucoma (POAG) is a chronic and
      progressive optic neuropathy of unknown etiology characterized by disc cupping, and often
      associated with visual field defects and elevated IOP. This disease is one of the leading
      causes of blindness worldwide.[Kwon YH et al.] Approximately 18% to 36% of the general
      population are corticosteroid responders. This response is increased to 46% to 92% in
      patients with POAG.[Tripathi RC et al.] Asthma is the most common chronic respiratory illness
      in Canada, affecting approximately 10% of the population. For the majority of these patients,
      long-term inhaled corticosteroids (ICS) are standard of care to prevent acute asthma
      exacerbations.[Kim H and Mazza J] Although the systemic absorption of inhaled and nasal
      steroids has been established, the clinically relevant ocular side effects are poorly
      defined. [Cave A et al.; Allen DB et al.] A large prospective study in 1995 by Samiy et al
      reported no statistically significant increase of IOP in 187 patients without glaucoma taking
      inhaled steroids for various pulmonary conditions.[Samiy N et al.] However, six cases of
      increased IOP associated with combined nasal and inhaled steroid use in non-glaucomatous
      patients have been reported. [Dreyer EB; Desnoeck M et al.; Opatowsky I et al.] A large
      case-control study in 1997 suggested that current users of high doses of ICS prescribed
      regularly for 3 or more months were at increased risk of OHT or OAG (OR 1.44; 95% CI
      1.01-2.06).[Garbe E et al.] In contrast, Gozalez et al. conducted a nested case-control study
      in 2010 with Quebec data which showed current and continuous use of ICS did not result in
      increased risk of glaucoma or raised IOP requiring treatment.[Gonzalez AV et al.] Similarly,
      Duh et al. reported no association between inhaled budesonide daily therapy and increased IOP
      in 1255 asthmatic patients.[Duh MS et al.] Further, a prospective population-based cohort
      study published in 2012 suggested no association between the development of OAG and ICS in
      the elderly.[Marcus MW et al.] In 2013, our group published a randomized double-masked
      controlled trial that showed no evidence of IOP elevation after 6 weeks use of beclomethasone
      nasal spray in 19 patients with OHT and POAG.[Yuen D et al.] The purpose of the current study
      protocol would be to extend the study to investigate ICS in the same patient population.

      To date, the effect of inhaled corticosteroids in those with pre-existing OHT or POAG remains
      uncertain. Considering the large number of patients on inhaled steroids, investigating the
      use of inhaled steroid in glaucoma patients could have significant clinical impact. This
      study was designed to evaluate the effect of inhaled fluticasone propionate on intraocular
      pressure (IOP) in patients with OHT or controlled open-angle glaucoma (OAG).

      Patient randomization was performed by an independent Research Coordinator in a separate
      physical space and kept sealed from the principal study investigators, who assessed and
      recorded outcome measures, until the completion of study data collection. IOP was measured in
      a masked fashion, using a second observer to record values. Two measurements within 1 mmHg
      were averaged for each data point. With a sample size of 8 patients per interventional arm,
      the study is powered at 0.80 to detect an elevation of 3.2 mmHg (≥20%) from mean, assuming a
      standard deviation of 2.5 mmHg. Baseline data will be compared between groups using the
      student's t test and Fisher exact test. A 2-sided p value of &lt;0.05 will be considered
      statistically significant. The primary outcome measure (mean IOP) will be assessed using a
      1-sided Student t test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure</measure>
    <time_frame>week 6</time_frame>
    <description>Masked assessment of intraocular pressure using goldmann application tonometry. Mean of 2 measurements within 1 mmHg will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Visual Acuity</measure>
    <time_frame>week 6</time_frame>
    <description>best corrected logMAR visual acuity for each eye. 20/20 vision corresponds with a logMAR score of 0, while negative logMAR scores indicate better than 20/20 vision, values &gt; 0.5 correspond with low vision, and values &gt; 1.3 correspond with blindness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>from baseline to week 6</time_frame>
    <description>subjective (reported) and objective (slit lamp examination) side-effects attributable to study medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure Elevation &gt;20% From Baseline</measure>
    <time_frame>within 6-week observation period</time_frame>
    <description>Participants with 2 consecutive intraocular pressure measurements exceeding 20% increase from baseline were discontinued from study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>Completion of study, up to 6 weeks</time_frame>
    <description>Adherence was calculated from self-reported study diaries and correlated to a counter that measured number of inhaled puffs built into the placebo metered-dose inhalers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate inhaler</intervention_name>
    <description>fluticasone propionate 250 µg metered-dose inhaler</description>
    <arm_group_label>Fluticasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo inhaler</intervention_name>
    <description>saline metered dose inhaler</description>
    <arm_group_label>Saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 85 years, inclusive

          -  Mild-moderate open-angle glaucoma/ocular hypertension with cup:disc ratio &lt;0.85
             vertically and humphrey visual field mean deviation &gt;-12.00 (BOTH EYES must meet this
             criteria for patient to be included)

          -  Glaucoma well-controlled, defined by IOP &lt; 21 mmHg and at target with no visual
             field/disc progression for at least 6 months (BOTH EYES must meet this criteria for
             patient to be included)

        Exclusion Criteria:

          -  Any form of steroid medication use within the prior 6 weeks

          -  Any previous intra-ocular surgery or refractive surgery in the study eye

          -  no light perception (i.e. blindness) in either eye

          -  unwilling/unable to give consent

          -  unwilling to accept randomization

          -  patient potentially unavailable for follow-up visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham E Trope, MD,PhD,FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto Western Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>ALFANO JE. CHANGES IN THE INTRAOCULAR PRESSURE ASSOCIATED WITH SYSTEMIC STEROID THERAPY. Am J Ophthalmol. 1963 Aug;56:245-7.</citation>
    <PMID>14061602</PMID>
  </reference>
  <reference>
    <citation>BERNSTEIN HN, SCHWARTZ B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol. 1962 Dec;68:742-53.</citation>
    <PMID>13967694</PMID>
  </reference>
  <reference>
    <citation>BERNSTEIN HN, MILLS DW, BECKER B. Steroid-induced elevation of intraocular pressure. Arch Ophthalmol. 1963 Jul;70:15-8.</citation>
    <PMID>13967695</PMID>
  </reference>
  <reference>
    <citation>BECKER B, MILLS DW. CORTICOSTEROIDS AND INTRAOCULAR PRESSURE. Arch Ophthalmol. 1963 Oct;70:500-7.</citation>
    <PMID>14078872</PMID>
  </reference>
  <reference>
    <citation>BECKER B, MILLS DW. ELEVATED INTRAOCULAR PRESSURE FOLLOWING CORTICOSTEROID EYE DROPS. JAMA. 1963 Sep 14;185:884-6.</citation>
    <PMID>14043096</PMID>
  </reference>
  <reference>
    <citation>ARMALY MF. EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE. Arch Ophthalmol. 1963 Oct;70:482-91.</citation>
    <PMID>14078870</PMID>
  </reference>
  <reference>
    <citation>ARMALY MF. EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. II. THE EFFECT OF DEXAMETHASONE IN THE GLAUCOMATOUS EYE. Arch Ophthalmol. 1963 Oct;70:492-9.</citation>
    <PMID>14078871</PMID>
  </reference>
  <reference>
    <citation>Buckley RJ. Allergic eye disease--a clinical challenge. Clin Exp Allergy. 1998 Dec;28 Suppl 6:39-43.</citation>
    <PMID>9988434</PMID>
  </reference>
  <reference>
    <citation>Herschler J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol. 1972 Sep;74(3):501-4.</citation>
    <PMID>5053696</PMID>
  </reference>
  <reference>
    <citation>Kalina RE. Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol. 1969 Jun;81(6):788-90.</citation>
    <PMID>5783749</PMID>
  </reference>
  <reference>
    <citation>Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S. Extensive visual loss with topical facial steroids. Eye (Lond). 1993;7 ( Pt 5):664-6.</citation>
    <PMID>8287990</PMID>
  </reference>
  <reference>
    <citation>Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med. 2009 Mar 12;360(11):1113-24. doi: 10.1056/NEJMra0804630. Review.</citation>
    <PMID>19279343</PMID>
  </reference>
  <reference>
    <citation>Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999 Dec;15(6):439-50. Review.</citation>
    <PMID>10641955</PMID>
  </reference>
  <reference>
    <citation>Kim H, Mazza J. Asthma. Allergy Asthma Clin Immunol. 2011 Nov 10;7 Suppl 1:S2. doi: 10.1186/1710-1492-7-S1-S2.</citation>
    <PMID>22165976</PMID>
  </reference>
  <reference>
    <citation>Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther. 1999 Sep;83(3):153-79. Review.</citation>
    <PMID>10576291</PMID>
  </reference>
  <reference>
    <citation>Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003 Sep;112(3 Suppl):S1-40. Review.</citation>
    <PMID>14515117</PMID>
  </reference>
  <reference>
    <citation>Samiy N, Walton DS, Dreyer EB. Inhaled steroids: effect on intraocular pressure in patients without glaucoma. Can J Ophthalmol. 1996 Apr;31(3):120-3.</citation>
    <PMID>8743219</PMID>
  </reference>
  <reference>
    <citation>Dreyer EB. Inhaled steroid use and glaucoma. N Engl J Med. 1993 Dec 9;329(24):1822.</citation>
    <PMID>8232507</PMID>
  </reference>
  <reference>
    <citation>Desnoeck M, Casteels I, Casteels K. Intraocular pressure elevation in a child due to the use of inhalation steroids--a case report. Bull Soc Belge Ophtalmol. 2001;(280):97-100.</citation>
    <PMID>11486469</PMID>
  </reference>
  <reference>
    <citation>Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995 Feb;102(2):177-9.</citation>
    <PMID>7862403</PMID>
  </reference>
  <reference>
    <citation>Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997 Mar 5;277(9):722-7.</citation>
    <PMID>9042844</PMID>
  </reference>
  <reference>
    <citation>Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther. 2010 Apr;23(2):65-70. doi: 10.1016/j.pupt.2009.10.014. Epub 2009 Nov 1.</citation>
    <PMID>19887116</PMID>
  </reference>
  <reference>
    <citation>Duh MS, Walker AM, Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol. 2000 Nov;85(5):356-61.</citation>
    <PMID>11101175</PMID>
  </reference>
  <reference>
    <citation>Marcus MW, Müskens RP, Ramdas WD, Wolfs RC, De Jong PT, Vingerling JR, Hofman A, Stricker BH, Jansonius NM. Corticosteroids and open-angle glaucoma in the elderly: a population-based cohort study. Drugs Aging. 2012 Dec;29(12):963-70. doi: 10.1007/s40266-012-0029-9.</citation>
    <PMID>23150239</PMID>
  </reference>
  <reference>
    <citation>Yuen D, Buys YM, Jin YP, Alasbali T, Trope GE. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma. J Glaucoma. 2013 Feb;22(2):84-7. doi: 10.1097/IJG.0b013e3182254811.</citation>
    <PMID>21716127</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <results_first_submitted>July 1, 2015</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2019</results_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Graham E Trope</investigator_full_name>
    <investigator_title>Toronto Western Hospital Glaucoma Service Co-Director</investigator_title>
  </responsible_party>
  <keyword>Corticosteroids</keyword>
  <keyword>Bronchodilator Agents</keyword>
  <keyword>Intraocular Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1,960 records of glaucoma patients with scheduled visits in a university-based glaucoma clinic were screened between August 1, 2014 and November 7, 2014.</recruitment_details>
      <pre_assignment_details>22 consented to participate and 20 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Steroid Inhaler</title>
          <description>randomized to 6 weeks of 1 puff twice daily 250ug fluticasone propionate inhaled.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Inhaler</title>
          <description>randomized to 6 weeks of 1 puff twice daily saline inhaled.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone</title>
          <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo</title>
          <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="9.0"/>
                    <measurement group_id="B2" value="65.7" spread="11.0"/>
                    <measurement group_id="B3" value="65.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean intraocular pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="3.0"/>
                    <measurement group_id="B2" value="15.6" spread="3.6"/>
                    <measurement group_id="B3" value="15.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of ocular hypotensive medications</title>
          <units>medication classes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.7"/>
                    <measurement group_id="B2" value="1.3" spread="1.4"/>
                    <measurement group_id="B3" value="1.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior laser trabeculoplasty</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean central corneal thickness</title>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="553.1" spread="31.7"/>
                    <measurement group_id="B2" value="549.1" spread="30.8"/>
                    <measurement group_id="B3" value="551.1" spread="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean cup-disc ratio</title>
          <description>The cup-to-disc ratio compares the diameter of the cup portion of the optic disc with the total diameter of the optic disc. A cup-to-disc ratio &gt; 0.5 might be indicative of glaucoma.</description>
          <units>cup:disc ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.49" spread="0.2"/>
                    <measurement group_id="B2" value="0.38" spread="0.2"/>
                    <measurement group_id="B3" value="0.44" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean visual field mean deviation</title>
          <units>decibels (dB)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.72" spread="2.6"/>
                    <measurement group_id="B2" value="-1.13" spread="2.5"/>
                    <measurement group_id="B3" value="-0.92" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean logMAR visual acuity</title>
          <description>20/20 vision corresponds with a logMAR score of 0, while negative logMAR scores indicate better than 20/20 vision, values &gt; 0.5 correspond with low vision, and values &gt; 1.3 correspond with blindness.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.19" spread="0.1"/>
                    <measurement group_id="B2" value="0.18" spread="0.1"/>
                    <measurement group_id="B3" value="0.18" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ocular Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary Open-Angle Glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pigment Dispersion Glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudoexfoliative Glaucoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Intraocular Pressure</title>
        <description>Masked assessment of intraocular pressure using goldmann application tonometry. Mean of 2 measurements within 1 mmHg will be recorded.</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure</title>
          <description>Masked assessment of intraocular pressure using goldmann application tonometry. Mean of 2 measurements within 1 mmHg will be recorded.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="2.4"/>
                    <measurement group_id="O2" value="14.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Visual Acuity</title>
        <description>best corrected logMAR visual acuity for each eye. 20/20 vision corresponds with a logMAR score of 0, while negative logMAR scores indicate better than 20/20 vision, values &gt; 0.5 correspond with low vision, and values &gt; 1.3 correspond with blindness.</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Acuity</title>
          <description>best corrected logMAR visual acuity for each eye. 20/20 vision corresponds with a logMAR score of 0, while negative logMAR scores indicate better than 20/20 vision, values &gt; 0.5 correspond with low vision, and values &gt; 1.3 correspond with blindness.</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.12"/>
                    <measurement group_id="O2" value="0.15" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>subjective (reported) and objective (slit lamp examination) side-effects attributable to study medications</description>
        <time_frame>from baseline to week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>subjective (reported) and objective (slit lamp examination) side-effects attributable to study medications</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>lens opacity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>throat discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>difficulty sleeping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no adverse effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure Elevation &gt;20% From Baseline</title>
        <description>Participants with 2 consecutive intraocular pressure measurements exceeding 20% increase from baseline were discontinued from study.</description>
        <time_frame>within 6-week observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure Elevation &gt;20% From Baseline</title>
          <description>Participants with 2 consecutive intraocular pressure measurements exceeding 20% increase from baseline were discontinued from study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>elevation &gt;20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no elevation &gt;20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence</title>
        <description>Adherence was calculated from self-reported study diaries and correlated to a counter that measured number of inhaled puffs built into the placebo metered-dose inhalers</description>
        <time_frame>Completion of study, up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>Adherence was calculated from self-reported study diaries and correlated to a counter that measured number of inhaled puffs built into the placebo metered-dose inhalers</description>
          <units>percentage of required doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" spread="7.1"/>
                    <measurement group_id="O2" value="96.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks of study</time_frame>
      <desc>Patients were asked about any side-effects they were experiencing at each biweekly study visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone</title>
          <description>participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo</title>
          <description>participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>difficulty sleeping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Graham Trope</name_or_title>
      <organization>Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada</organization>
      <phone>1-416-603-5117</phone>
      <email>graham.trope@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

